These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 1971090

  • 1. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE, Relling MV.
    Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
    [Abstract] [Full Text] [Related]

  • 2. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 3. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M.
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [Abstract] [Full Text] [Related]

  • 4. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 6. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD.
    Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
    [Abstract] [Full Text] [Related]

  • 7. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC.
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [Abstract] [Full Text] [Related]

  • 8. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC, Gonzalez FJ, Demierre A, Meyer UA.
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [Abstract] [Full Text] [Related]

  • 9. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA.
    J Biol Chem; 1990 Oct 05; 265(28):17209-14. PubMed ID: 2211621
    [Abstract] [Full Text] [Related]

  • 10. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F.
    J Pharmacol Exp Ther; 1995 Jul 05; 274(1):516-20. PubMed ID: 7616439
    [Abstract] [Full Text] [Related]

  • 11. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA.
    DNA Cell Biol; 1991 Oct 05; 10(8):545-58. PubMed ID: 1681816
    [Abstract] [Full Text] [Related]

  • 12. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent.
    Wedlund PJ, Kimura S, Gonzalez FJ, Nebert DW.
    Pharmacogenetics; 1994 Feb 05; 4(1):21-6. PubMed ID: 7516235
    [Abstract] [Full Text] [Related]

  • 13. Association of a 12.5-kilobase allele of the MspI restriction fragment length polymorphism of the C6 gene in patients with total deficiency of the sixth component of complement.
    Potter PC, Warburton C, Würzner R, Orren A, Di Scipio R.
    Exp Clin Immunogenet; 1993 Feb 05; 10(1):38-44. PubMed ID: 7691111
    [Abstract] [Full Text] [Related]

  • 14. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR.
    Pharmacogenetics; 1991 Oct 05; 1(1):33-41. PubMed ID: 1688241
    [Abstract] [Full Text] [Related]

  • 15. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans.
    Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, Kamataki T.
    J Pharmacol Exp Ther; 1999 Apr 05; 289(1):437-42. PubMed ID: 10087035
    [Abstract] [Full Text] [Related]

  • 16. Carrier detection in severe (type III) von Willebrand disease using two intragenic restriction fragment length polymorphisms.
    Bahnak BR, Lavergne JM, Verweij CL, Rothschild C, Pannekoek H, Larrieu MJ, Meyer D.
    Thromb Haemost; 1988 Oct 31; 60(2):178-81. PubMed ID: 2905841
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec 31; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 18. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I, Kanazawa I.
    Adv Neurol; 1993 Dec 31; 60():338-42. PubMed ID: 8420147
    [Abstract] [Full Text] [Related]

  • 19. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK.
    Pharmacogenetics; 1995 Aug 31; 5(4):215-23. PubMed ID: 8528268
    [Abstract] [Full Text] [Related]

  • 20. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
    Zimmermann T, Schlenk R, Pfaff G, Lach P, Wildfeuer A.
    Arzneimittelforschung; 1995 Jan 31; 45(1):41-3. PubMed ID: 7893267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.